×
About 17,555 results

ALLMedicine™ Plasminogen Center

Research & Reviews  5,970 results

The comparison of mechanical thrombectomy and symptomatic therapy on early outcome of a...
https://doi.org/10.1016/j.clineuro.2022.107378
Clinical Neurology and Neurosurgery; Ahmetović H, Jerković A et. al.

Aug 7th, 2022 - Multiple randomized trials have confirmed that endovascular thrombectomy (ET) is an effective treatment method for patients with acute ischemic stroke (AIS) caused by large vessel occlusion (LVO). However, patients older than eighty years of age s...

Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19.
https://doi.org/10.2174/1871530322666220801102402
Endocrine, Metabolic & Immune Disorders Drug Targets; Al-Kuraishy HM, Al-Gareeb AI et. al.

Aug 6th, 2022 - Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory distress syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibr...

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
https://doi.org/10.1161/JAHA.122.025198
Journal of the American Heart Association; Luo S, Vasbinder A et. al.

Aug 5th, 2022 - Background Venous thromboembolism (VTE) contributes significantly to COVID-19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) r...

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke
https://clinicaltrials.gov/ct2/show/NCT03734640

Aug 3rd, 2022 - Research question: Patients receiving thrombolytic therapy (tissue plasminogen activator [tPA]) for acute ischaemic stroke (AIS), have been monitored with a high intensity schedule of vital signs and neurologic assessments, which often requires 1:...

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
https://clinicaltrials.gov/ct2/show/NCT04663750

Aug 3rd, 2022 - SMH is a rare but devastating complication of wet AMD. Untreated, SMH typically leads to permanent and severe loss of vision, ranging from 6/30 (approximately 20% normal vision) to only being able to perceive light versus dark (no useful vision). ...

see more →

Guidelines  5 results

Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of ...
https://doi.org/10.1016/j.annemergmed.2015.06.031
Annals of Emergency Medicine; , Brown MD et. al.

Aug 26th, 2015 - Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.|2015| ,Brown MD,Burton JH,Nazarian DJ,Promes SB,|administration & dosage,adverse effects,therapeutic use,diag...

Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Pa...
https://doi.org/10.3171/2014.7.PEDS14322
Journal of Neurosurgery. Pediatrics; Mazzola CA, Choudhri AF et. al.

May 20th, 2015 - The objective of this systematic review and analysis was to answer the following question: What are the optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants? Both the US National Library of Medicine and the Coc...

Consensus statement on the use of intravenous recombinant tissue plasminogen activator ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493470
CNS Neuroscience & Therapeutics; Xu AD, Wang YJ et. al.

May 29th, 2013 - The last update of the consensus statement on intravenous recombinant tissue plasminogen activator (IV rt-PA) for acute ischemic stroke (AIS) by the Chinese Stroke Therapy Expert Panel was published in 2006. Great progress has been made since then...

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278065
Chest Lansberg MG, O'Donnell MJ et. al.

Feb 15th, 2012 - This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). We generated treatment recommendations (Grade 1) and suggestions (Grade 2) based on high (A), moderate (B), and ...

Expansion of the time window for treatment of acute ischemic stroke with intravenous ti...
https://doi.org/10.1161/STROKEAHA.109.192535
Stroke Del Zoppo GJ, Saver JL et. al.

May 30th, 2009 - Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.|2009|Del Zoppo GJ,Saver JL,Jauch EC,Adams HP, ,|...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  463 results

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
https://clinicaltrials.gov/ct2/show/NCT04663750

Aug 3rd, 2022 - SMH is a rare but devastating complication of wet AMD. Untreated, SMH typically leads to permanent and severe loss of vision, ranging from 6/30 (approximately 20% normal vision) to only being able to perceive light versus dark (no useful vision). ...

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke
https://clinicaltrials.gov/ct2/show/NCT03734640

Aug 3rd, 2022 - Research question: Patients receiving thrombolytic therapy (tissue plasminogen activator [tPA]) for acute ischaemic stroke (AIS), have been monitored with a high intensity schedule of vital signs and neurologic assessments, which often requires 1:...

Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
https://clinicaltrials.gov/ct2/show/NCT05024253

Aug 2nd, 2022 - Resection of bone tumors is commonly associated with considerable intra and post-operative blood loss due to extensive soft tissue dissection, multiple bone osteotomies, prolonged operative time. The intraoperative use of limb tourniquet to reduce...

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
https://clinicaltrials.gov/ct2/show/NCT05395351

Jul 28th, 2022 - The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom on...

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
https://clinicaltrials.gov/ct2/show/NCT05401149

Jul 28th, 2022 - The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom onset in a real-wo...

see more →

News  576 results

Early Post-Stroke Gene Expression May Predict Stroke Outcomes
https://www.medscape.com/viewarticle/976479

Jun 30th, 2022 - The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways The study suggests genes involved in regulating immune response after ischemic stroke (IS) may impact long-term function...

Malpractice Case: How Diagnosis and Handoff Mishaps Led to Patient's Severe Stroke Outcome
https://www.medscape.com/viewarticle/975740

Jun 22nd, 2022 - It's well understood that physicians have limited time to treat patients with stroke before the disease progresses and outcomes can worsen. This case illustrates how differing opinions by remote and in-person physicians — followed by system breakd...

Synthetic, Botanical Agents Emerging as Promising Melasma Treatments
https://www.medscape.com/viewarticle/974105

May 17th, 2022 - BOSTON — Though hydroquinone, retinoids, steroids, and triple combination cream remain gold standards for the topical treatment of melasma, new synthetic and botanical topicals are emerging as adjuvant and alternative treatments, according to Nada...

Synthetic, botanical agents emerging as promising melasma treatments
https://www.mdedge.com/dermatology/article/254236/melasma/synthetic-botanical-agents-emerging-promising-melasma-treatments
Doug Brunk

Apr 29th, 2022 - BOSTON – Though hydroquinone, retinoids, steroids, and triple combination cream remain gold standards for the topical treatment of melasma, new synthetic and botanical topicals are emerging as adjuvant and alternative treatments, according to Nada.

Are Thrombolytics for Stroke Safe for Patients on NOACs?
https://www.medscape.com/viewarticle/969163

Feb 25th, 2022 - Recent use of non-vitamin K antagonist oral anticoagulants (NOACs) is not associated with increased risk for bleeding following treatment with intravenous alteplase for ischemic stroke, new data suggest. In a prespecified, retrospective analysis o...

see more →

Patient Education  2 results see all →